Blood Pressure Disorders Drug Development Pipeline Review 2018 - A1M Pharma, Acceleron Pharma, Ache Laboratorios Farmaceuticos, Actelion Pharmaceuticals, Aerogen, Anavex Life Sciences, AnGes, Arena Pharmaceuticals

Blood Pressure Disorders Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for blood pressure disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hypertension, pulmonary arterial hypertension (PAH) and hypotension, and features dormant and discontinued products.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in the body and the condition of the kidneys, nervous system, and blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels.

Get More Information Download Sample Copy at https://www.premiummarketinsights.com/sample/GBI00004580?source=OpenPR-HM

Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically do not occur until high blood pressure has reached a severe stage. There are 253 products in development for this indication.

PAH is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). There are 92 products in development for this indication.

Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Pipeline activity is much lower for hypotension than for hypertension or PAH with only seven products in development for this indication.

Molecular targets acted on by products in development for blood pressure disorders include angiotensin receptors, tyrosine protein kinases and phosphodiesterases. Companies operating in this pipeline space include Gmax Biopharm, Actelion Pharmaceuticals and Theravance Biopharma.

Scope

-Which companies are the most active within the pipeline for blood pressure disorders-
-Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication-
-To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies-
-What are the most important R&D milestones and data publications to have happened within this field-

Reasons to buy

-Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
-Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
-Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
-Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Inquire before Buying at https://www.premiummarketinsights.com/inquiry/GBI00004580?source=OpenPR-HM

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 10
2.1 Blood Pressure Disorder Report Coverage 10
2.2 Hypertension-Overview 10
2.3 Hypotension-Overview 10
2.4 Pulmonary Arterial Hypertension-Overview 10
3 Therapeutics Development 11
3.1 Hypertension 11
3.2 Hypotension 32
3.3 Pulmonary Arterial Hypertension 35
4 Therapeutics Assessment 45
4.1 Hypertension 45
4.2 Hypotension 61
4.3 Pulmonary Arterial Hypertension 67
5 Companies Involved in Therapeutics Development 77
5.1 Hypertension 77
5.2 Hypotension 129
5.3 Pulmonary Arterial Hypertension 131
6 Dormant Projects 156
6.1 Hypertension 156
6.2 Hypotension 169
6.3 Pulmonary Arterial Hypertension 169
7 Discontinued Products 173
7.1 Hypertension 173
7.2 Pulmonary Arterial Hypertension 175
8 Product Development Milestones 176
8.1 Hypertension 176
8.2 Hypotension 187
8.3 Pulmonary Arterial Hypertension 197
9 Appendix 212
9.1 Methodology 212
9.2 Coverage 212
9.3 Secondary Research 212
9.4 Primary Research 212
9.5 Expert Panel Validation 212
9.6 Contact Us 213
9.7 Disclaimer 213

Purchase this Premium Research Report at https://www.premiummarketinsights.com/buy/GBI00004580

Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.

Pune, India

This release was published on openPR.